Combined SGLT2 and Renin-Angiotensin System Inhibitors Versus Monotherapy for Preventing End-Stage Kidney Disease in Type 2 Diabetes and Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Background: Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) are the leading causes of end-stage kidney disease (ESKD) globally. Although renin-angiotensin system (RAS) inhibitors (ACE inhibitors or ARBs) represent standard therapy, substantial residual renal risk persists. This meta-analysis evaluated whether adding sodium-glucose cotransporter-2 (SGLT2) inhibitors to RAS blockade reduces ESKD progression compared to RAS monotherapy in adults with T2DM and/or CKD. Methods: We searched PubMed up to November 2026 and screened reference lists of prior reviews for randomized controlled trials (RCTs) and cohort studies comparing combined SGLT2 and RAS inhibition against RAS monotherapy in adults with T2DM and/or CKD. The primary outcome was ESKD incidence. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects inverse-variance model. Results: Three large-scale studies comprising 121,455 patients (7,531 receiving combination therapy and 113,924 receiving RAS monotherapy) met eligibility criteria. Combined SGLT2 and RAS inhibition significantly reduced ESKD risk by 35% compared to RAS monotherapy (pooled HR: 0.65; 95% CI: 0.55–0.77; P < 0.0001). No statistical heterogeneity was observed across the studies (I² = 0.0%, P = 0.7875). Conclusion: Adding SGLT2 inhibitors to standard RAS blockade significantly lowers the risk of ESKD progression in adults with T2DM and/or CKD, supporting early dual therapy for optimal renoprotection.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-13
DOI
https://doi.org/10.5281/zenodo.24207148
Primary Topic
Chronic Kidney Disease and Diabetes
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Combined SGLT2 and Renin-Angiotensin System Inhibitors Versus Monotherapy for Preventing End-Stage Kidney Disease in Type 2 Diabetes and Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Yousef Ismail Ibrahim Jbor
5 links
Zenodo (CERN European Organization for Nuclear Research)
Chronic Kidney Disease and Diabetes
preprint

Combined SGLT2 and Renin-Angiotensin System Inhibitors Versus Monotherapy for Preventing End-Stage Kidney Disease in Type 2 Diabetes and Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Yousef Ismail Ibrahim Jbor
preprint en

Abstract

Background: Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) are the leading causes of end-stage kidney disease (ESKD) globally. Although renin-angiotensin system (RAS) inhibitors (ACE inhibitors or ARBs) represent standard therapy, substantial residual renal risk persists. This meta-analysis evaluated whether adding sodium-glucose cotransporter-2 (SGLT2) inhibitors to RAS blockade reduces ESKD progression compared to RAS monotherapy in adults with T2DM and/or CKD. Methods: We searched PubMed up to November 2026 and screened reference lists of prior reviews for randomized controlled trials (RCTs) and cohort studies comparing combined SGLT2 and RAS inhibition against RAS monotherapy in adults with T2DM and/or CKD. The primary outcome was ESKD incidence. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects inverse-variance model. Results: Three large-scale studies comprising 121,455 patients (7,531 receiving combination therapy and 113,924 receiving RAS monotherapy) met eligibility criteria. Combined SGLT2 and RAS inhibition significantly reduced ESKD risk by 35% compared to RAS monotherapy (pooled HR: 0.65; 95% CI: 0.55–0.77; P < 0.0001). No statistical heterogeneity was observed across the studies (I² = 0.0%, P = 0.7875). Conclusion: Adding SGLT2 inhibitors to standard RAS blockade significantly lowers the risk of ESKD progression in adults with T2DM and/or CKD, supporting early dual therapy for optimal renoprotection.

Zenodo (CERN European Organization for Nuclear Research)
Alexandria University (EG)
Good health and well-being
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon